Micell Technologies raised $25.8 million in a new round of equity and debt financing, according to an SEC filing posted this week.
Micell currently produces the MiStent SES sirolimus eluting absorbable polymer coronary stent, designed to treat coronary artery disease.
Money in the round came from 51 anonymous sources, according to an SEC filing, with the company looking to raise another $4.2 million before closing the round.
